Meeting
2023 ASCO Genitourinary Cancers Symposium
The comprehensive analysis of relationship between gut microbiome and treatment outcome of androgen deprivation therapy (ADT)-based treatment in patients with metastatic castration-sensitive and -resistant prostate cancer.
Authors
Nobuaki Matsubara
National Cancer Center Hospital East, Chiba, Japan
Nobuaki Matsubara , Shunsuke Sakai , Riu Yamashita , Toshihiro Misumi , Masaki Shiota , Masatoshi Eto , Taigo Kato , Takahiro Osawa , Takashige Abe , Nobuo Shinohara , Koshiro Nishimoto , Yota Yasumizu , Nobuyuki Tanaka , Mototsugu Oya , Takao Fujisawa , Satoshi Horasawa , Yoshiaki Nakamura , Takayuki Yoshino , Norio Nonomura
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 213)
DOI
10.1200/JCO.2023.41.6_suppl.213
Abstract #
213
Poster Bd #
H2
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Management disparities in metastatic castrate-sensitive prostate cancer (mCSPC).
First Author: Nataliya Mar
Poster
2023 ASCO Annual Meeting
Enzalutamide, docetaxel and androgen deprivation (ENZADA trial) for metastatic castrate sensitive prostate cancer (mCSPC).
First Author: Earle F Burgess
Poster
2023 ASCO Annual Meeting
Early results from CASCARA: A phase 2 study of cabazitaxel/carboplatin plus abiraterone in high-volume metastatic castrate-sensitive prostate cancer (mCSPC).
First Author: Charles J. Ryan
Poster
2021 Genitourinary Cancers Symposium
Prescribing patterns in patients with metastatic castrate-sensitive prostate cancer (mCSPC).
First Author: Nataliya Mar